Skip to main content
Erschienen in: Journal of Neurology 9/2013

01.09.2013 | Original Communication

Analysis of the visual system in Friedreich ataxia

verfasst von: Lauren A. Seyer, Kristin Galetta, James Wilson, Reiko Sakai, Susan Perlman, Katherine Mathews, George R. Wilmot, Christopher M. Gomez, Bernard Ravina, Theresa Zesiewicz, Khalaf O. Bushara, S. H. Subramony, Tetsuo Ashizawa, Martin B. Delatycki, Alicia Brocht, Laura J. Balcer, David R. Lynch

Erschienen in: Journal of Neurology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

To use optical coherence tomography (OCT) and contrast letter acuity to characterize vision loss in Friedreich ataxia (FRDA). High- and low-contrast letter acuity and neurological measures were assessed in 507 patients with FRDA. In addition, OCT was performed on 63 FRDA patients to evaluate retinal nerve fiber layer (RNFL) and macular thickness. Both OCT and acuity measures were analyzed in relation to genetic severity, neurologic function, and other disease features. High- and low-contrast letter acuity was significantly predicted by age and GAA repeat length, and highly correlated with neurological outcomes. When tested by OCT, 52.7 % of eyes (n = 110) had RNFL thickness values below the fifth percentile for age-matched controls. RNFL thickness was significantly lowest for those with worse scores on the Friedreich ataxia rating scale (FARS), worse performance measure composite Z 2 scores, and lower scores for high- and low-contrast acuity. In linear regression analysis, GAA repeat length and age independently predicted RNFL thickness. In a subcohort of participants, 21 % of eyes from adult subjects (n = 29 eyes) had macular thickness values below the first percentile for age-matched controls, suggesting that macular abnormalities can also be present in FRDA. Low-contrast acuity and RNFL thickness capture visual and neurologic function in FRDA, and reflect genetic severity and disease progression independently. This suggests that such measures are useful markers of neurologic progression in FRDA.
Literatur
1.
Zurück zum Zitat Lynch DR, Farmer JM, Balcer LJ, Wilson RB (2002) Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 59:743–747PubMedCrossRef Lynch DR, Farmer JM, Balcer LJ, Wilson RB (2002) Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 59:743–747PubMedCrossRef
2.
Zurück zum Zitat Schulz JB, Denmer T, Schols L et al (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719–1721PubMedCrossRef Schulz JB, Denmer T, Schols L et al (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719–1721PubMedCrossRef
3.
Zurück zum Zitat Bidichandani SI, Ashizawa T, Patel PI (1997) Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triple-repeat expansion. Am J Hum Genet 60:1251–1256PubMed Bidichandani SI, Ashizawa T, Patel PI (1997) Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triple-repeat expansion. Am J Hum Genet 60:1251–1256PubMed
4.
Zurück zum Zitat Cossee M, Durr A, Schmitt M et al (1999) Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45:200–206PubMedCrossRef Cossee M, Durr A, Schmitt M et al (1999) Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45:200–206PubMedCrossRef
5.
Zurück zum Zitat Monros E, Molto MD, Martinez F et al (1997) Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet 61:101–110PubMedCrossRef Monros E, Molto MD, Martinez F et al (1997) Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet 61:101–110PubMedCrossRef
6.
Zurück zum Zitat Babady NE, Carelle N, Wells RD et al (2007) Advancements in the pathophysiology of Friedreich’s ataxia and new prospects for treatments. Molec Genet Metabolism 92:23–35CrossRef Babady NE, Carelle N, Wells RD et al (2007) Advancements in the pathophysiology of Friedreich’s ataxia and new prospects for treatments. Molec Genet Metabolism 92:23–35CrossRef
7.
Zurück zum Zitat Cooper JM, Schapira AH (2003) Friedreich’s ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. BioFactors 18:163–171PubMedCrossRef Cooper JM, Schapira AH (2003) Friedreich’s ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. BioFactors 18:163–171PubMedCrossRef
8.
Zurück zum Zitat Harding AE (1981) Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104:589–620PubMedCrossRef Harding AE (1981) Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104:589–620PubMedCrossRef
9.
10.
Zurück zum Zitat Fahey MC, Cremer PD, Aw ST et al (2008) Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain 131:1035–1045PubMedCrossRef Fahey MC, Cremer PD, Aw ST et al (2008) Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain 131:1035–1045PubMedCrossRef
11.
Zurück zum Zitat Fortuna F, Barboni P, Liguori R et al (2009) Visual system involvement in patients with Friedreich’s ataxia. Brain 132(part 1):116–123PubMed Fortuna F, Barboni P, Liguori R et al (2009) Visual system involvement in patients with Friedreich’s ataxia. Brain 132(part 1):116–123PubMed
13.
Zurück zum Zitat Carelli V, Ross-Cisneros FN, Sadun AA (2002) Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int 40:573–584PubMedCrossRef Carelli V, Ross-Cisneros FN, Sadun AA (2002) Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int 40:573–584PubMedCrossRef
14.
Zurück zum Zitat Teesalu P, Tuulonen A, Airaksinen PJ (2000) Optical coherence tomography and localized defects of the retinal nerve fiber layer. Acta Ophthalmol Scand 78:49–52PubMedCrossRef Teesalu P, Tuulonen A, Airaksinen PJ (2000) Optical coherence tomography and localized defects of the retinal nerve fiber layer. Acta Ophthalmol Scand 78:49–52PubMedCrossRef
15.
Zurück zum Zitat Syc SB, Warner CV, Hiremath GS et al (2010) Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 0:1–11 Syc SB, Warner CV, Hiremath GS et al (2010) Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 0:1–11
16.
Zurück zum Zitat Fisher JB, Jacobs DA, Markowitz CE et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113(2):324–332PubMedCrossRef Fisher JB, Jacobs DA, Markowitz CE et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113(2):324–332PubMedCrossRef
17.
Zurück zum Zitat Cettomai D, Pulicken M, Gordon-Lipkin E et al (2008) Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 65:1218–1222PubMedCrossRef Cettomai D, Pulicken M, Gordon-Lipkin E et al (2008) Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 65:1218–1222PubMedCrossRef
18.
Zurück zum Zitat Kanamori A, Nakamura M, Escano MF et al (2003) Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol 135:513–520PubMedCrossRef Kanamori A, Nakamura M, Escano MF et al (2003) Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol 135:513–520PubMedCrossRef
19.
Zurück zum Zitat Talman LS, Bisker ER, Sackel DJ et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. 67:749–760PubMed Talman LS, Bisker ER, Sackel DJ et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. 67:749–760PubMed
20.
Zurück zum Zitat Trip SA, Schlottmann PG, Jones SJ et al (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58(3):383–391PubMedCrossRef Trip SA, Schlottmann PG, Jones SJ et al (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58(3):383–391PubMedCrossRef
21.
Zurück zum Zitat Costello F, Coupland S, Hodge W et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969PubMedCrossRef Costello F, Coupland S, Hodge W et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969PubMedCrossRef
22.
Zurück zum Zitat Lynch DR, Farmer JM, Tsou AY et al (2006) Measuring Friedreich ataxia: complementary features of examination performance measures. Neurology 66:1711–1716PubMedCrossRef Lynch DR, Farmer JM, Tsou AY et al (2006) Measuring Friedreich ataxia: complementary features of examination performance measures. Neurology 66:1711–1716PubMedCrossRef
23.
Zurück zum Zitat Subramony SH, May W, Lynch D et al (2005) Cooperative ataxia group. measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64:1261–1262PubMedCrossRef Subramony SH, May W, Lynch D et al (2005) Cooperative ataxia group. measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64:1261–1262PubMedCrossRef
24.
Zurück zum Zitat Friedman LS, Farmer JM, Perlman S et al (2010) Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 25:426–432PubMedCrossRef Friedman LS, Farmer JM, Perlman S et al (2010) Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 25:426–432PubMedCrossRef
25.
Zurück zum Zitat Deutsch EC, Santani AB, Perlman SL et al (2010) A rapid, non-invasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol. Gen. Metab. 101:238–245CrossRef Deutsch EC, Santani AB, Perlman SL et al (2010) A rapid, non-invasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol. Gen. Metab. 101:238–245CrossRef
26.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRef
27.
Zurück zum Zitat Lynch DR, Farmer JM, Rochestie D, Balcer LJ (2002) Contrast letter acuity as a measure of visual dysfunction in patients with Friedreich ataxia. J Neuroophthalmol 22:270–274PubMedCrossRef Lynch DR, Farmer JM, Rochestie D, Balcer LJ (2002) Contrast letter acuity as a measure of visual dysfunction in patients with Friedreich ataxia. J Neuroophthalmol 22:270–274PubMedCrossRef
28.
Zurück zum Zitat Ratchford JN, Quigg ME, Conger A et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73:302–308PubMedCrossRef Ratchford JN, Quigg ME, Conger A et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73:302–308PubMedCrossRef
29.
Zurück zum Zitat McCormack ML, Guttmann RP, Schumann M et al (2000) Frataxin point mutations in two patients with Friedreich’s ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 68:661–664PubMedCrossRef McCormack ML, Guttmann RP, Schumann M et al (2000) Frataxin point mutations in two patients with Friedreich’s ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 68:661–664PubMedCrossRef
30.
Zurück zum Zitat Pinto F, Amantini A, deScisciolo G et al (1988) Visual involvement in Friedreich’s ataxia: pERG and VEP study. Eur Neurol 28(5):246–251PubMedCrossRef Pinto F, Amantini A, deScisciolo G et al (1988) Visual involvement in Friedreich’s ataxia: pERG and VEP study. Eur Neurol 28(5):246–251PubMedCrossRef
Metadaten
Titel
Analysis of the visual system in Friedreich ataxia
verfasst von
Lauren A. Seyer
Kristin Galetta
James Wilson
Reiko Sakai
Susan Perlman
Katherine Mathews
George R. Wilmot
Christopher M. Gomez
Bernard Ravina
Theresa Zesiewicz
Khalaf O. Bushara
S. H. Subramony
Tetsuo Ashizawa
Martin B. Delatycki
Alicia Brocht
Laura J. Balcer
David R. Lynch
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 9/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-013-6978-z

Weitere Artikel der Ausgabe 9/2013

Journal of Neurology 9/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.